The IPO Buzz: Biotechs Iambic & City Therapeutics on Center Stage
Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are in the spotlight this week as the only two deals on the IPO Calendar so far. Both biotechs are set to go public in a year that’s seen a resurgence in the volume of biotech sector IPOs, compared with 2025. This week’s light IPO Calendar is coming against the backdrop of the Columbus Day holiday today, when the feder..
Read more October 12, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Iambic Therapeutics | IAM | 9.4 | $ 150.0 mil | 10/15/2026 Thursday | S/O | S/O |
| City Therapeutics | CTY | 9.7 | $ 175.0 mil | 10/16/2026 Friday | S/O | S/O |
| Bitari | BIAI | 4.3 | $ 30.0 mil | 10/19/2026 Week of | S/O | S/O |
Last 100 IPOs - October 11, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 39 |
| Number Down: | 59 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | 0.03% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 11, 2026
| Number of IPOs priced (Excluding 152 units) : | 127 |
| Number Up: | 47 |
| Number Down: | 78 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | -1.02% |
| The Nasdaq Composite Index YTD % Change | 35.22% |